

LEVELS OF EVIDENCE

Level Description

1

1 - Drug is FDA-approved and biomarker is standard of care (SOC) for this indication (excluding chemotherapeutic drugs and hormone therapies)

2A

2A - Drug is FDA-approved and the associated biomarker is predictive of response by NCCN for this indication

2B

2B - Drug is FDA-approved and the associated biomarker is predictive of response by NCCN for a different indication

3A

3A - Clinical evidence supports the biomarker as being predictive of response to a drug for this indication

3B

3B - Clinical evidence supports the biomarker as being predictive of response to a drug for a different indication

4

4 - Compelling preclinical evidence and/or case study reports support the biomarker as being predictive of response to this drug

R1

R1 - Standard of care biomarker predictive of resistance to an FDA-approved drug for this indication including biomarkers described by the NCCN

R2

R2 - Clinical evidence supports a biomarker not included in NCCN and not standard of care as of being predictive of resistance to an FDA-approved drug